Navigation Links
CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings

ll be made available on CuraGen's website at http://www.curagen.com, or by emailing . info@curagen.com

About Belinostat

Belinostat is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, including 5-FU, carboplatin, paclitaxel, cis-retinoic acid, azacitidine and Velcade(R) (bortezomib) for Injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes and have been shown to: arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote

differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents.

Intravenous belinostat is currently being evaluated in multiple clinical trials as a potential treatment for multiple myeloma, T- and B-cell lymphomas, AML, mesothelioma, liver, colorectal, ovarian cancers, either alone or in combination with anti-cancer therapies. An oral formulation of belinostat is also being evaluated in a Phase I clinical trial for patients with advanced solid tumors. In August 2004, CuraGen signed a Clinical Trials Agreement with the NCI under which the NCI will sponsor several clinical trials to investigate belinostat for the treatment of various cancers, both as a single- agent and in combination chemotherapy regimens. In May 2005, TopoTarget announced the signing of a Cooperative Research and Development Agreement (CRADA) with the NCI to conduct preclinical and nonclinical studies on belinostat in order to better understand its anti-tumor activity and to provide supporting information for clinical trials.

About CuraGen

CuraGen Corporati
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:5/16/2008)...nd customer thought leaders -, SAN FRANCISCO, May...ader and trusted resource for clinical trial manag...prestigious academic medical centers, research,ins... group meeting in San,Francisco. The Velos eResear...boratively manage thousands of clinical trials., ...
(Date:5/16/2008)...r PEGylation of a Small Molecule with ...OS, Calif., May 16 /- Nekta...results today from a Phase 1,study of NKTR- 102, P...ti-tumor activity in patients with refractory soli...s small molecule PEGylation technology,produced an...
(Date:5/16/2008)... Significant Reductions in Selected ...ublished in 2008 Proceedings of the American Socie... SAN DIEGO, May 16 /- ADVE... today that, in a registrational bioequivalence,cl... significant reduction,in general disorders and ad...
(Date:5/15/2008)...FirstCall/ -- Medivation, Inc.,(Nasdaq: MDVN ) to...clinical,trial of its novel androgen receptor anta...entation at the 44th American Society of Clinical ...sion title: New Targeted Strategies for Patients w..., June 2 at 11:30 a.m. Central Time Abstract titl...
Breaking Medicine Technology:Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade 28TM 29 3260 1PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade 28TM 29 3260 2PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade 28TM 29 3260 3 2437 million financing for company based on macular degeneration research 3256 1 2437 million financing for company based on macular degeneration research 3256 2Lunch Lady Challenges Schools Families to Make Kids Nutrition a Priority 3251 1Lunch Lady Challenges Schools Families to Make Kids Nutrition a Priority 3251 2Angel Flight West Recognizes Southern California Pilots at 24th Anniversary 3246 1Angel Flight West Recognizes Southern California Pilots at 24th Anniversary 3246 2
(Date:5/16/2008)...EWPORT BEACH, Calif., May 16 /PRNewswire-FirstCall...P ) announced today the promotion of David,M. Boit... Officer. "Dave,has made a tremendous contribution...y our strong investment growth and diversification... over $1 billion in accretive,investments for NHP,...
(Date:5/16/2008)...AN DIEGO, May 16 /PRNewswire-FirstCall/ -- CryoCor...cused on the treatment of cardiac,arrhythmias, ann...ers of,CryoCor common stock filed a complaint in t...ty of San Diego, naming as defendants each member ...Boston Scientific Corporation.,The complaint is st...
(Date:5/16/2008)...ment guidelines quickly disseminated to community ...16 (HealthDay News) -- Partnerships between major ...e a quick and effective way to spread cancer treat... Center in Philadelphia. , Most new cancer trea...ost cancer care is provided at community hospitals...
(Date:5/16/2008)...ismatch in some early stage cases makes therapy of...RIDAY, May 16 (HealthDay News) -- Colon cancer pat...need to receive chemotherapy. In fact, not only do..., it may actually harm them, a new study found. ,...ncer], then you should not be treated with chemoth...
Breaking Medicine News(10 mins):Health News:David M. Boitano Promoted to Senior Vice President 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4Health News:Partnerships Effective Communicators of Cancer Advances 2Health News:Not All Colon Cancer Patients Need Chemotherapy: Study 2
...eening system combining digital photography with I...method to screen for a common childhood oral disea...ty toddlers. Early childhood dental caries (ECC... tooth decay, results from prolonged exposure to s...
...study published in the journal, Cell Metabolism, r...ion in the zebrafish that are remarkably similar t...es disease that could aid in finding new therapies...ead to the aquarium fish becoming an important ani...
... mothers may someday get a personalized menu of fo...netic makeup as a result of new research at Washin... Researchers used transparent fish embryos to dev...genes and diet interact to cause birth defects. "...
...can children with asthma make more clinic visits t... severity.// Asthma has been on the rise for the ... especially high prevalence. A study in the August...hat Puerto Rican children with asthma make more cl...
Other Medicine News:Health News:New Screening System For Early Detection Of Dental Caries in Toddlers 2Health News:New Screening System For Early Detection Of Dental Caries in Toddlers 3Health News:New Studies On Zebrafish Could Aid in Treating Birth Defects 2Health News:New Studies On Zebrafish Could Aid in Treating Birth Defects 3Health News:New Studies On Zebrafish Could Aid in Treating Birth Defects 4Health News:Unmasking Nutrition's Role in Genes and Birth Defects 2Health News:Unmasking Nutrition's Role in Genes and Birth Defects 3Health News:Children of Different Race Show Different Patterns of Asthma Care 2
Self retaining brain retractor.
The Budde Halo brain retractor is designed for use in all intercranial procedures where retraction of delicate brain tissue is required.
Langenbeck periosteal elevators, wide, blade width 11/16" (17 mm), length 7 1/2" (191 mm).
Cushing periosteal elevators, Gutsch handle, sharp, narrow, blade width 3/16" (5 mm), length 7 5/8" (194 mm).
Medicine Products: